The Application Notebook
This application note describes the transfer of a conventional LC method for the analysis of antihistaminic drugs from an Agilent 1100 Series Quaternary LC to an Agilent 1260 Infinity II LC, and demonstrates that equivalent results can be obtained.
Sonja Krieger, Agilent Technologies Inc.
This application note describes the transfer of a conventional LC method for the analysis of antihistaminic drugs from an Agilent 1100 Series Quaternary LC to an Agilent 1260 Infinity II LC, and demonstrates that equivalent results can be obtained.
Introduction
Instrument-to-instrument method transfer is an important topic for all laboratories throughout different industries (1). One example is the transfer of conventional LC methods from older equipment such as the Agilent 1100 Series Quaternary LC, to new instruments such as the Agilent 1260 Infinity II LC. This application note (2)describes the analysis of antihistaminic drugs using an 1100 Series Quaternary LC. The method is transferred without any changes to the 1260 Infinity II LC, and equivalent results in terms of retention time and resolution are obtained. Furthermore, the conventional LC analysis of antihistaminic drugs can be transferred to UHPLC conditions, optimized for resolution as well as for speed, using the Agilent 1260 Infinity II LC.
Experimental Conditions
Conventional LC analysis of the antihistaminic drugs tripelenamine, chlorpheniramine, tetracaine, and promethazine was achieved with the Agilent 1100 Series Quaternary LC as well as the Agilent 1260 Infinity II LC. An Agilent ZORBAX SB-C18 column (4.6 × 150 mm, 5-μm) was used with a gradient of 25 mM potassium dihydrogen phosphate in water (pH 3) and acetonitrile at a flow rate of 1.5 mL/min and a temperature of 40 °C. Diode array detection was performed at 204 nm.
Results
The conventional LC analysis of antihistaminic drugs was transferred without any method changes from an Agilent 1100 Series Quaternary LC to an Agilent 1260 Infinity II LC. By using the Agilent 1260 Infinity II LC, excellent retention time and area precision was achieved. Figure 1 compares the retention times of the antihistaminic drugs obtained using the Agilent 1100 Series Quaternary LC and the Agilent 1260 Infinity II LC. With a maximum deviation of -1.7%, excellent agreement of retention times was observed. Further, a slight increase in resolution was achieved using the Agilent 1260 Infinity II LC. This proves the equivalency of the 1260 Infinity II LC compared to the 1100 Series Quaternary LC for the analysis of antihistaminic drugs.
Figure 1: Conventional LC analysis of antihistaminic drugs on an Agilent 1100 Series Quaternary LC and an Agilent 1260 Infinity II LC.Figure 1: Conventional LC analysis of antihistaminic drugs on an Agilent 1100 Series Quaternary LC and an Agilent 1260 Infinity II LC.
With a pressure range of up to 600 bar, the Agilent 1260 Infinity II LC also enables UHPLC analyses to be performed using Agilent InfinityLab Poroshell columns. The transfer of the conventional LC analysis of antihistaminic drugs to UHPLC conditions, optimized for resolution as well as for speed, offers the option to increase peak resolution and at the same time reduce analysis time and solvent use.
Conclusions
The transfer of a conventional LC method for the analysis of antihistaminic drugs from an Agilent 1100 Series Quaternary LC to an Agilent 1260 Infinity II LC showed a maximum retention time deviation of -1.7% as well as a slight increase in resolution, and thereby proves the equivalency of the 1260 Infinity II LC compared to the 1100 Series Quaternary LC for the analysis of antihistaminic drugs.
References
Agilent Technologies, Inc.
5301 Stevens Creek Blvd., Santa Clara, California 95051, USA
Tel: (800) 227 9770
Website: www.agilent.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.